Newron Overhauls Board with Industry Veterans as Longtime Directors Exit
Event summary
- Newron Pharmaceuticals to replace two long-serving board members, Patrick Langlois (18 years) and Luca Benatti (14 years), at its April 23, 2026 AGM.
- George Garibaldi and Paolo Zocchi nominated as independent, non-executive directors, bringing CNS drug development and capital markets expertise.
- Garibaldi has 30+ years in CNS drug development, co-founded StutterSenseAI and Noema Pharma, and led teams at Roche, Janssen, and Novartis.
- Zocchi has 35+ years in financial services, led 15 IPOs, and advised pharmaceutical companies including Sanofi and Bayer.
- Full AGM agenda and 2025 financial results to be published March 24, 2026.
The big picture
Newron's board refresh comes as it advances its lead compound, evenamide, through pivotal trials for treatment-resistant schizophrenia. The additions of Garibaldi and Zocchi suggest a focus on strengthening both scientific and financial governance as the company navigates late-stage clinical development. The move reflects broader trends in biotech governance, where specialized expertise is increasingly valued over generalist experience.
What we're watching
- Strategic Alignment
- How Garibaldi and Zocchi's expertise will shape Newron's development of evenamide and other CNS therapies.
- Financial Strategy
- Whether Zocchi's capital markets experience will accelerate Newron's fundraising or partnership efforts.
- Regulatory Progress
- The pace at which Newron advances its ENIGMA-TRS Phase III program under the new board leadership.